Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Faslodex
is pretty exciting. It has been called "pure antiestrogen."
I think, in fact, it’s better called an estrogen receptor down
regulator. And, unlike tamoxifen and other SERMs that just get on
the receptor complex and block it and block its action at some point
down the chain, Faslodex actually results in total disappearance
of estrogen receptor in cells so they’re down regulated, they
disappear out of the cell, and potentially that has the possibility
of producing even more depravation of estrogen for the breast cancer
cells, and potentially even better results. And in some of the animal
models, for example the xenograph models, or the tamoxifen-dependent
cell lines that can be produced in animal or in vitro models, where
tamoxifen or other SERMs will make breast cancer cells grow and
sort of feed them, Faslodex stops them. And in addition, in some
of the animal models, xenograph models, Faslodex can prevent the
formation of tumors and prevent it indefinitely; whereas, other
SERMs prevent it but the tumors come along later. So, I think there’s
theoretical and animal model and cell line model information to
suggest that Faslodex could be a step up.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
